eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
18 hedge funds and large institutions have $251K invested in eFFECTOR Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
6% more funds holding
Funds holding: 17 → 18 (+1)
98% less capital invested
Capital invested by funds: $13.5M → $251K (-$13.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$836K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$146K |
| 3 |
HF
HRT Financial
New York
|
+$51.1K |
| 4 |
Jane Street
New York
|
+$44.3K |
| 5 |
VF
Virtu Financial
New York
|
+$42.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.21M |
| 2 |
SC
Stempoint Capital
New York
|
-$1.91M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.37M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$474K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$178K |
EFTR Hedge Fund Activity: Q2 2024 in Review
18 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q2 2024, worth a combined $251K — down 98% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new EFTR positions and 7 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $836K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.21M sold.
- 18 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q2 2024, up from 17 in Q1 2024.
- Funds reported $251K of eFFECTOR Therapeutics, Inc. Common Stock stock for Q2 2024, down 98% quarter-over-quarter.
- 8 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q2 2024 and 7 closed out, a net change of +1 holder.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q2 2024 was Sabby Management, an estimated $836K added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q2 2024 was Armistice Capital, an estimated $3.21M sold.
Based on aggregated 13F filings for Q2 2024.